Wiebke Hollburg

Learn More
1079 Background: First-line Bev-Pac is an established treatment option in HER2-negative mBC, significantly improving progression-free survival (PFS) and response rate (RR) versus Pac alone. Two(More)
Philadelphia-negative myeloproliferative neoplasms (MPN) comprise a heterogeneous group of chronic hematological malignancies with significant variations in clinical characteristics. Due to the long(More)
  • 1